Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-A251 in Advanced or Metastatic HER2-Expressing Solid Tumors
NCT07228247Phase 2Recruiting
- Sponsor
- HUTCHMED
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of HMPL-A251 in solid tumor, sponsored by HUTCHMED. Started Dec 2025; status: recruiting.
02
Drugs
HMPL-A251
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07228247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228247.